A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab

Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, constituting approximately 13% of all hematologic malignancies. Isatuximab is a monoclonal antibody targeting the CD38 protein on myeloma cells, causi...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda, Jason Ta, Benjamin Tzer-Ming Chuang, Yin Mon Myat, Aishwarya Hanspal, Kyaw Zin Thein, Thura Win Htut
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Open Exploration Publishing Inc. 2025-03-01
Rangatū:	Exploration of Targeted Anti-tumor Therapy
Ngā marau:	multiple myeloma isatuximab pneumonia upper respiratory tract infections (urtis) venous thromboembolism (vte) randomized controlled trials (rcts) adverse events hematologic malignancy
Urunga tuihono:	https://www.explorationpub.com/uploads/Article/A1002300/1002300.pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!